Role of prothrombin complex concentrate in perioperative coagulation therapy

Table 1 Factor contents of commercially available PCCs

	FII IU/ml	FVII IU/ml	FIX IU/ml	FX IU/ml	PC IU/ml	PS IU/ml	Hepari U/ml
4-factor PCC
Beriplex/Kcentra (CSL Behring, Germany)	20–48	10–25	20–31	22–60	15–45	13–26	0.4–2
Octaplex (Octapharma, Austria)	11–38	9–24	25	18–30	7–31	7–32	<15
Prothromplex Total (Baxter, Austria)	24–45	25	30	30	>20	N.Q.	<15
PPSB-HT (Nichiyaku, Japan)	20	20	20	20	15–45	N.Q.	5
Cofact (Sanquin, Netherlands)	14–35	7–20	25	14–35	11–39	1–8	None
3-factor PCC
Bebulin (Baxter, USA)	30	3–5	25	35	N.Q.	N.Q.	3.75
Profilnine (Octapharma, Austria)	37	3	25	16	N.Q.	N.Q.	None
Activated PCC
FEIBA (Baxter, USA)	+	+ (FVIIa)	+	+ (FXa)	N.Q.	N.Q.	None

Other PCC products are also available in different countries. PCCs containing heparin are contraindicated in patients with heparin-induced thrombocytopenia. The potency of each PCC vial is according to the FIX activity except for FEIBA, which is dosed according to FVIII bypassing activity unit. Data are shown based on the prescribing information for each product; actual factor contents may vary for each vial.
PC/PS protein C/protein S, N.Q. not quantified.

ISSN: 2052-0492